Integer (NYSE:ITGR) Upgraded at Freedom Capital

Freedom Capital upgraded shares of Integer (NYSE:ITGR) to a strong-buy rating in a report released on Wednesday morning,Zacks.com reports.

A number of other research analysts have also weighed in on the stock. Zacks Research raised shares of Integer from a “strong sell” rating to a “hold” rating in a report on Monday, July 20th. Truist Financial increased their price objective on shares of Integer from $97.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. KeyCorp reissued an “overweight” rating and issued a $104.00 price objective on shares of Integer in a research note on Tuesday. Citigroup boosted their target price on shares of Integer from $92.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, July 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Integer in a research report on Thursday, June 18th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and seven have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.00.

Integer Trading Up 1.1%

Shares of ITGR stock opened at $98.61 on Wednesday. The company has a current ratio of 3.75, a quick ratio of 2.38 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $3.35 billion, a price-to-earnings ratio of 24.59, a price-to-earnings-growth ratio of 2.32 and a beta of 0.64. Integer has a 12-month low of $62.00 and a 12-month high of $111.99. The stock’s 50-day moving average price is $92.47 and its 200-day moving average price is $88.16.

Integer (NYSE:ITGR) last announced its quarterly earnings results on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). Integer had a net margin of 7.64% and a return on equity of 12.83%. The firm had revenue of $439.58 million for the quarter, compared to the consensus estimate of $426.48 million. During the same period in the previous year, the company posted $1.31 earnings per share. Integer’s quarterly revenue was up .5% on a year-over-year basis. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. Equities research analysts predict that Integer will post 6.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Integer

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Integer by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 3,886,150 shares of the medical equipment provider’s stock worth $304,791,000 after purchasing an additional 14,465 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Integer by 6.5% during the first quarter. Dimensional Fund Advisors LP now owns 1,484,396 shares of the medical equipment provider’s stock valued at $130,620,000 after buying an additional 90,277 shares during the period. State Street Corp grew its stake in shares of Integer by 3.7% during the fourth quarter. State Street Corp now owns 1,371,767 shares of the medical equipment provider’s stock valued at $107,588,000 after buying an additional 48,463 shares during the last quarter. Viking Global Investors LP raised its holdings in shares of Integer by 9.1% in the second quarter. Viking Global Investors LP now owns 1,283,965 shares of the medical equipment provider’s stock worth $157,889,000 after buying an additional 106,692 shares during the period. Finally, Irenic Capital Management LP purchased a new stake in shares of Integer in the fourth quarter worth approximately $99,109,000. 99.29% of the stock is currently owned by institutional investors.

About Integer

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.